MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its pipeline is built around muscarinic receptor programs, including ML-007C-MA for schizophrenia and Alzheimer's disease psychosis and ML-004 for autism spectrum disorders.
Fiscal year 2025 · change from previous year
Development 2024–2025
Business
Share of revenueDrug candidates under preclinical and clinical development for CNS indications.
Internal platform used to identify circuit-specific pathways and new indications.
In-licensed and acquired technology rights supporting the pipeline.
Strategic collaborations and licensing arrangements that may support development.
Customers
MapLight does not yet sell commercial products, so its direct customers are not patients or hospitals today. Its economic stakeholders are future pharmaceutical buyers, payors, and potential licensing or collaboration partners that would support development and eventual commercialization of its CNS programs.
Patients with schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorders who would use approved therapies if development succeeds.
Potential partners that may fund, license, or co-develop MapLight's programs to reduce development risk and extend reach.
Public and private payors that would need to cover any approved therapy, affecting adoption and pricing power.
Psychiatrists, neurologists, and specialty care providers who would prescribe and administer approved CNS treatments.
Strategy
MapLight's strategy is to advance its muscarinic receptor pipeline through clinical development while expanding the number of indications it can address. The company is also focused on preserving capital, securing additional funding or collaborations, and building intellectual property protection until it can reach commercialization, if ever.
Clinical progress is the main value driver for a company with no commercial revenue.
More indications can improve the probability of success and expand the addressable market.
The company will need substantial additional funding before any product revenue is possible.
Patent protection and development execution are essential to future commercialization value.
Geography
MapLight is a U.S.-based company and currently expects commercialization efforts, if any, to begin in the United States. Its reported exposure is therefore concentrated in U.S. clinical development, regulatory review, and future market access, with additional dependence on third-party CROs, CMOs, and collaborators that may operate globally.
Risks
MapLight faces the classic risks of a clinical-stage biotech: no product revenue, heavy cash burn, and uncertainty around clinical success, regulatory approval, and reimbursement. Its muscarinic CNS programs also face competitive pressure, IP risk, and dependence on third-party manufacturers and research vendors, which can disrupt timelines and increase costs.
- Clinical development failureImpact: CriticalLikelihood: High
The company is still testing product candidates and may not demonstrate safety or efficacy.
Exposure - Financing and dilution riskImpact: HighLikelihood: High
The company expects substantial additional capital needs before any product sales.
Exposure - Competitive displacementImpact: HighLikelihood: Medium
Other biotech and pharma companies may reach the market faster or with better therapies.
Exposure - Intellectual property protectionImpact: HighLikelihood: Medium
Weak or challenged patents could allow competitors to copy or block commercialization.
Exposure - Third-party manufacturing and CRO dependenceImpact: MediumLikelihood: Medium
Clinical supply and trial execution rely on external vendors and contractors.
Exposure
Accounting
Judgemental itemsClinical trial, CRO, and manufacturing costs are accrued based on estimates and can shift period to period.
Impact: Affects operating loss and comparability across quarters
The Stellaromics stake is marked through equity-method earnings/losses and basis differences.
Impact: Can create non-cash volatility in other income/expense
Employee and director equity awards are a meaningful non-cash expense for a pre-revenue biotech.
Impact: Inflates operating expenses without immediate cash outflow
Development and regulatory milestones tied to acquired assets may trigger future payments or share issuance.
Impact: Can affect cash needs and dilution
Management's funding-through-2027 estimate depends on IPO proceeds and spending assumptions.
Impact: Important for liquidity assessment and financing risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Minerva Neurosciences, Inc.
NERV · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
LB Pharmaceuticals Inc
LBRX · Pharmaceutical Preparations
Neuphoria Therapeutics Inc.
NEUP · Pharmaceutical Preparations
Anavex Life Sciences Corp
AVXL · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026